Anti-tumor necrosis factor blocking agents in the treatment of systemic vasculitis

Marzouq Qubti, Philip Seo

Research output: Contribution to journalArticlepeer-review


The primary systemic vasculitides are idiopathic disorders characterized by the inflammatory destruction of blood vessel walls. Many of these disorders are treated with high-dose glucocorticoids and cytotoxic agents which, while effective, are associated with substantial morbidity, particularly for patients who experience recurrent flares requiring chronic therapy. Therefore, attention has turned towards biologic therapies that abrogate specific elements in the inflammatory cascade. Tumor necrosis factor-a is a cytokine that is central to systemic inflammation in many diseases. This article will review the role played by tumor necrosis factor-a in the pathogenesis of systemic vasculitis, and attempt to define a role for blockade of tumor necrosis factor-a in the treatment of patients with these diseases.

Original languageEnglish (US)
Pages (from-to)423-428
Number of pages6
JournalCurrent Immunology Reviews
Issue number4
StatePublished - Nov 1 2011


  • ANCA-associated vasculitis
  • Giant cell arteritis
  • Tumor necrosis factor
  • Vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Anti-tumor necrosis factor blocking agents in the treatment of systemic vasculitis'. Together they form a unique fingerprint.

Cite this